Table 2.
GMD difference analysis among MAP, SCZ and control recruits.
| Brain region | The mean GMD | BA | Voxels | MNI coordinates (x, y, z) | Peak F value | Group mean difference/significance | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| MAP patients | SCZ patients | Control | MAP-control/P | SCZ-control/P | MAP-SCZ/P | |||||
| L-opr-IFG | 0.45 | 0.38 | 0.42 | 45 | 46 | −57, 9, 23 | 10.63 | 0.03/ P=0.036 | −0.04/P=0.014 | 0.07/ P<0.001 |
| B-MSFG | 0.63 | 0.53 | 0.52 | 9 | 67 | 3, 53, 27 | 12.57 | 0.11/ P<0.001 | 0.01/ P=1.000 | 0.10/ P<0.001 |
| B-AC | 0.53 | 0.43 | 0.47 | 24 | 606 | 2, 9, 30 | 20.85 | 0.06/ P=0.032 | −0.04/P=0.197 | 0.10/ P<0.001 |
| R-MFG | 0.71 | 0.53 | 0.72 | 9 | 132 | 38, 18, 44 | 14.85 | −0.01/P=1.000 | −0.19/P<0.001 | 0.18/ P<0.001 |
GMD – gray matter density; MAP – methamphetamine-associated psychosis; SCZ – schizophrenia; BA – bradmann; MNI – Montreal Neurological Institute; B – bilateral; opr-IFG – operculum inferior frontal gyrus; MSFG – medial superior frontal gyrus; AC – anterior cingulate; MFG – middle frontal gyrus.